STATICH Antiplatelets: Underpowered Trial Leaves ICH Restart Dilemma Open
Analysis Anticoagulation / Hematology Inconclusive Grade: Very Low
Eilertsen H, Larsen KT, Forfang E, et al.
Aug 1, 2026 · Published in: Stroke
Also in Neurology / Neuropharmacology
Restarting antiplatelets after ICH: Safe or risky?
Prior IV thrombolysis does not dictate first-line thrombectomy technique
Analysis Neurology / Neuropharmacology Confirmatory Grade: Low
Mouyal SJ, Maïer B, Labreuche J, et al.
Jul 24, 2026 · Published in: European Stroke Journal
Does prior thrombolysis influence thrombectomy effectiveness in stroke recovery?
Nanocarrier Delivery Systems for Overcoming Epilepsy Treatment Barriers
Analysis Neurology / Neuropharmacology Hypothesis-generating Grade: Very Low
Chauhan A, Kumar A, Awasthi A, et al.
Jul 23, 2026 · Published in: The Journal of Pharmacy and Pharmacology
Nanocarriers show potential for improving epilepsy drug delivery.
Low-Dose Thrombolysis Plus Argatroban Signals Benefit in Ischemic Stroke
Analysis Neurology / Neuropharmacology Hypothesis-generating Grade: Very Low
Huang S, Wang X, Li D, et al.
Jul 18, 2026 · Published in: Medicine
Combining tenecteplase with argatroban might enhance stroke recovery.
CNS Hemorrhage Signal With MAPK-Pathway Inhibitors Demands Risk Stratification
Analysis Neurology / Neuropharmacology Hypothesis-generating Grade: Low
Damodharan S, Calderon A, Abdelbaki MS
Jul 15, 2026 · Published in: Journal of Neuro-oncology
MAPK-pathway inhibitors pose a serious intracranial hemorrhage risk in neuro-oncology.
D-Dimer/Fibrinogen Ratio Predicts Poor Post-Thrombolysis Stroke Outcomes
Analysis Neurology / Neuropharmacology Hypothesis-generating Grade: Low
Zhang X, Fu Y, Lu J
Jul 11, 2026 · Published in: Clinical and Applied Thrombosis/hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
New biomarker DFR predicts poor stroke outcomes post-thrombolysis.
Subcutaneous Natalizumab Cuts Chair Time, Cost, Boosts Quality of Life
Analysis Neurology / Neuropharmacology Confirmatory Grade: Low
Filippi M, Grimaldi LME, Brescia Morra V, et al.
Jul 10, 2026 · Published in: Journal of Neurology
Subcutaneous natalizumab streamlines MS care while enhancing patient experience.
Undiluted IV Push Valproic Acid Shows Favorable Safety Across 5500 Doses
Analysis Neurology / Neuropharmacology Confirmatory Grade: Low
Rollins S, Radosevich JJ, Sammani N, et al.
Jul 10, 2026 · Published in: Journal of Neurology
Undiluted IV push valproic acid proves safe for rapid seizure treatment.
Subcutaneous Levodopa Infusion Cuts OFF Time in Real-World Parkinson Care
Analysis Neurology / Neuropharmacology Confirmatory Grade: Low
Ali A, Cheema WA, Shamoon M, et al.
Jul 7, 2026 · Published in: Medicine
New infusion therapy eases Parkinson's motor symptoms with tolerability challenges.
Most Post-Stroke Patients Miss Blood Pressure Targets in CONVINCE
Analysis Cardiology Confirmatory Grade: Moderate
Synnott P, Walsh C, Weimar C, et al.
Jul 6, 2026 · Published in: European Stroke Journal
Also in Neurology / Neuropharmacology
Most post-stroke patients miss new BP guidelines.
IV Thrombolysis Before Thrombectomy Improves Recanalization in Extended Window
Analysis Neurology / Neuropharmacology Confirmatory Grade: Low
Nicolini E, Ciacciarelli A, Pracucci G, et al.
Jul 2, 2026 · Published in: European Journal of Neurology
IVT pre-MT improves stroke recanalization success post-4.5 hours.
Serial Lamotrigine Levels Fail to Predict Pregnancy Seizures
Analysis Neurology / Neuropharmacology Confirmatory Grade: Moderate
Allotey J, Junaid F, Peréz T, et al.
Jun 25, 2026 · Published in: BMJ Neurology Open
Also in Pharmacokinetics / TDM, Women's Health / Reproductive
Baseline dosing outshines serum levels for predicting seizures in pregnancy.
Asundexian Cuts Recurrent Stroke Without Excess Bleeding
Analysis Anticoagulation / Hematology Practice-changing Grade: High
Sharma M, Dong Q, Hirano T, et al.
Apr 16, 2026 · Published in: N Engl J Med
Also in Neurology / Neuropharmacology
Added to antiplatelet therapy after noncardioembolic stroke, asundexian lowered recurrent ischemic stroke from 8.4% to 6.2% with no increase in major bleeding.
Plasma p-tau217 Clocks Estimate Timing of Alzheimer Symptom Onset
Analysis Neurology / Neuropharmacology Hypothesis-generating Grade: Moderate
Petersen KK, Milà-Alomà M, Li Y, et al.
Feb 19, 2026 · Published in: Nature Medicine
This work demonstrates that a single blood-based %p-tau217 measurement can estimate not only whether but approximately when a cognitively unimpaired person will develop symptomatic Alzheimer disease, with implications for how pharmacists interpret emerging blood biomarker tests and screen for anti-amyloid therapy candidates.
Plasma p-tau217 Discriminates Early-Onset Alzheimer's in Real-World Clinic
Analysis Neurology / Neuropharmacology Confirmatory Grade: Low
Chatterjee P, Ivanic S, Southon A, et al.
Sep 1, 2025 · Published in: Journal of Alzheimer's Disease
This real-world diagnostic study extends plasma p-tau217 validation to early-onset Alzheimer's disease and flags severe renal impairment as a false-positive risk relevant to biomarker interpretation.